Patents are legal documents drawn up by inventors and lawyers and granted by various patent offices around the world, to protect the inventors' intellectual property. The short description accompanying each patent in this Patents section is therefore taken from the legal document as is, with minor corrections for Greek symbols and obvious spelling errors. The patents included in this section may be for material products (defensins or defensin-like peptides or nucleic acid sequences, synthetic or natural) or for novel methods of detecting, quantitating, synthesizing, or delivering antimicrobial peptides/nucleic acid sequences in general. The curators' criterion for inclusion in this section is broader for novel methods than for material products, in the hope that these methods may in future be similarly applied to defensins.

Patents in which the defensins or defensin-like material products and methods as above are not novel, such as biomarker sets containing unmodified defensin or defensin-like peptides or oligonucleotides, are excluded from this section. The exception to such exclusions is where the patent provides other novel defensin-related material products or methods in addition to those non-novel of the biomarker set itself. This exclusion is because the reasonable presence of defensin or defensin-like sequences or indeed any other sequences in patented biomarker sets is necessarily attributed to some prior discovery of disease state correlation with such sequences. The curators have observed therefore that the novel discovery in biomarker-related patents is often the method of biomarker array analysis and validation as well as its resultant implications for diagnostics and prognostics. The expert evaluation of such biomarker analysis and validation is well outside the scope of the Defensins Knowledgebase. The reader is respectfully referred to a biomarker database specific to the disease to perform his own assessment of the validity of the biomarker.

Methods not pertaining to the antimicrobial activity of defensins, but where defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences are suggested in some unambiguous detail to play a useful role in the method, with or without supporting experimental evidence, are included as well in this section. Patents in which natural defensins are up/downregulated in a clearly defined signal transduction pathway as a result of the unrelated patented novel compound or method are also included. And lastly, all patents showing experimental work done with defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences, where such peptides or nucleic acid sequences are not the experimental controls, are included without exception.

The data in this section have been extracted from the academic version of SciFinder Scholar 2007 and from public Google search - a wide range of defensin-related patents are included.


Results 51 - 60 of 333

<< Previous | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | Next >>

Last updated: 20th February 2008

Patent No.: WO 069750
Therapeutic composition with nanoscale activation agents.
Applicant: Joyce TH (2005)
The present invention relates to a composition and method for therapeutic treatment of humans and other mammals. The therapeutic composition of the present invention comprises an encapsulation vesicle, an activation agent such as a nanotube associated with the encapsulation vesicle, a bioactive agent, and an optional targeting ligand. The targeting ligand may be attached to either the activation agent or the encapsulation vesicle. The encapsulation vesicle selectively releases the bioactive agent to achieve a targeted application of the therapeutic or diagnostic potential for the bioactive agent, such as to destroy a diseased cell. The activation agent is activated by an endogenous or exogenous activation condition.

Patent No.: WO 068653
Polymorphisms in the defensin genes in determining the risk of cardiovascular diseases including acute myocardial infarction and coronary heart disease.
Applicant: Salonen JT, Pirskanen M, Haarus J, Tuomainen T-P, Yunus F (2005)
The invention provides a method of identifying a subject's susceptibility or predisposition to, or risk of, developing cardiovascular diseases such as myocardial infarction (MI) or coronary heart disease (CHD) by detecting gene polymorphisms and other gene mutations in a defensin gene from a biol. sample of the subject and obtaining information concerning the family and medical history, blood, serum, plasma and urinary analytes of the subject. The invention also provides a multivariate model, a combination or algorithm of variables which best describes the probability of CHD, esp. MI. The invention also relates to a test kit and software for accomplishing the method. The present invention also relates to a variant defensin gene. Methods of treatment of cardiovascular disease and its ramifications involving restoration of normal defensin levels are discussed.

Patent No.: WO 049637
Isolation and purification of alpha-defensins 1, 2 and 3 from human white blood cells by using acid extraction and chromatography.
Applicant: Guerrier L (2005)
The present invention provides methods for the isolation and purifn. of defensin polypeptides from white blood cells. More particularly, the present invention provides methods for the extn. and purifn. of human defensin polypeptides, i.e., alpha-defensins 1, 2 and 3, from intact white blood cells, without the need for nitrogen cavitation (Parr bomb) or mech. disruption, centrifugation and gel filtration. The method includes direct extn. by trifluoroacetic acid and acetonitrile followed by cation-exchange chromatog. and hydrophobic chromatog.

Patent No.: WO 034863
Antimalaria proteins derived from chitinase inhibitors, defensins, chitin-binding proteins, and cystein proteinases.
Applicant: Amoah V, Pandolfo A, Batkin T, Richards C (2005)
The present invention includes compounds useful for the control of malaria. One class of compds. includes cysteine proteases that are active against mosquitoes and a second class of compds. includes chimeric proteins having a defensin portion and either a chitinase inhibitor portion or a chitin binding protein portion, wherein the two portions are joined by a linker. Also included in the invention are methods of controlling malaria by application of compds. of the invention to mosquito habitats.

Patent No.: WO 025614
Nucleic acid vaccines encoding GM-CSF and TLR agonist as adjuvant against infection, cancer, allergy and autoimmune disease.
Applicant: Bembridge GP, Craigen JL (2005)
The present invention relates to improved nucleic acid vaccines, adjuvant systems, and processes for the preparation of such vaccines and adjuvant systems. In particular, the nucleic acid vaccines and adjuvant systems of the present invention comprise a combination of a nucleotide sequence encoding GM-CSF, or derivatives thereof, and toll-like receptor (TLR) agonists, or derivatives thereof.

Patent No.: WO 018701
Synergistic antimicrobial compositions and methods of inhibiting biofilm formation.
Applicant: Madhyastha S (2005)
A synergistic antimicrobial compn. for inhibiting biofilm formation includes an iron-sequestering glycoprotein, a cationic polypeptide and a chelating agent, or an iron-sequestering glycoprotein and a chelating agent, or an iron-sequestering glycoprotein and a cationic polypeptide. Addnl., surfactants and quaternary ammonium compds. may also be advantageously combined with iron-sequestering glycoproteins in an antimicrobial compn. Methods of using a synergistic compn. for inhibiting medical device biofilm formation are also disclosed. Antibacterial effects of ovotransferrin, protamine sulfate, and EDTA alone and in combinations on biofilm formation in catheter-assocd. bacteria such as Escherichia, Proteus, Pseudoinonas, Klebsiella, Enterococcus, and Staphylococcus are shown.

Patent No.: WO 013933
Mucoadhesive composition comprising polyacrylate and chemoattractant.
Applicant: Hubert P, Evrard B, Delattre L, Boniver J, Delvenne P, Noel A, Frankenne F, Foidart J-M (2005)
The invention relates to a mucoadhesive pharmaceutical composition comprising an acrylic acid containing polymer and a chemoattractant wherein the pH of the composition is 6 or less.

Patent No.: WO 012492
Human skin equivalents expressing exogenous KGF-2 polypeptides.
Applicant: Centanni JM, Allen-Hoffmann L (2005)
The present invention relates generally to compns. for wound closure. More specifically, the present invention provides human skin equiv. engineered to express exogenous polypeptides (e.g., antimicrobial polypeptides and keratinocyte growth factor 2) and compns. and methods for making human skin equiv. engineered to express exogenous polypeptides. In addn., the present invention provides methods for treatment of wounds with human skin equiv. engineered to express exogenous polypeptides. The present invention provides methods for providing cells expressing heterologous KGF-2 comprising: providing a host cell selected from the group consisting of primary keratinocytes and immortalized keratinocytes and an expression vector comprising a DNA sequence encoding KGF-2 operably linked to a regulatory sequence; transformation of cells with the expression vector and expression of KGF-2 in host cells. The invention further provides a method of treating wounds comprising: providing primary or immortalized keratinocytes expressing a exogenous antimicrobial polypeptide such as human beta-defensin 1, 2, 3, and human cathelicidin.

Patent No.: WO 004907
Immunostimulatory compositions comprising unmethylated CpG-containing oligonucleotide and packaged virus-like particles and therapeutical uses for allergies, tumors and viral diseases.
Applicant: Bachmann MF, Schwarz K (2005)
The invention provides a compn. for enhancing an immune response in an animal comprising (a) a virus-like particle (VLP), (b) an immunostimulatory nucleic acid, preferably an unmethylated CpG-contg. oligonucleotide, where the nucleic acid or oligonucleotide is coupled to, fused to, or otherwise attached to or enclosed by, i.e., bound to, and preferably packaged with the virus-like particle, (c) at least one antigen coupled or fused to the VLP or an antigen mixed with the VLP, and (d) at least one ligand for a TLR. The invention can be used to induce strong antibody and T cell responses particularly useful for the treatment of allergies, tumors and chronic viral diseases as well as other chronic diseases.

Patent No.: WO 004894
Method for inhibiting cell and tissue damage using protective proteins.
Applicant: Sanders MC, Ellis-Busby DL, Sebastian S, Havard JM, Colpas GJ (2005)
The present invention features methods of increasing cell or tissue viability by administering to the cell or tissue a protective protein. The invention also features methods of treating a condition characterized by cell or tissue damage in a subject by administering to the subject a protective protein. Protective proteins include p26, SicA, crystallins, and chimeric proteins contg. these proteins. Some of the protective proteins facilitate protein folding (p26, SicA) and some inhibit proteases (crystallins and chimeric pepstatin A-leupeptin-crystallin .alpha.A protein). Also included are chimeric proteins as well as methods of inhibiting proteolysis of a cationic antimicrobial peptide in a cell or tissue including contacting the cell or tissue with a protective protein, chimeric protein that includes the protective protein, or a biol. active fragment, variant, or deriv. thereof.